Here, we developed a fibrinogen‐based biomimetic hydrogel as a drug reservoir for the co‐delivery of the anti‐fibrotic agents PFD and Cap‐siIDO1‐Sfn‐CD62E (CISE) NPs to create an immune‐stimulated niche to attack residual tumor cells and suppress ccRCC recurrence after surgery (Figure 1). The gene discussed is SELE; the disease is neoplasm.